Investors

Several recent events demonstrate that investors are looking for hard evidence from GPs making ESG claims.

CPPIB's new growth equity unit appears to have swallowed up the pension manager's three-year-old venture capital business.

The Column Group is close to reaching its fundraising target of $600m apiece for its early-stage life science Fund V and later-stage Opportunity Fund III.

As is usually the case, increased rules mean higher compliance costs for those advisers who fall under regulation. For the biggest firms in the industry, those costs can be handled, but for smaller shops, and especially emerging managers, those costs could prove harmful.

ESG considerations and diversity among management teams rank low as a priority when sourcing managers, according to a new survey conducted by law firm Seward & Kissel.

VC funds performed admirably during the Global Financial Crisis and produced stellar returns in the following years, so you shouldn't be overly concerned about current economic uncertainty.

'About six or seven leading LPs' have joined an effort to create an ESG due diligence questionnaire tailored to the venture capital industry.

Australia’s biggest superannuation fund plans to grow its private equity portfolio from about $9bn to $18bn over the next two years.

Massachusetts Pension Reserves Investment Management Board, which recently backed two new funds from Union Square Ventures, is looking to give chief investment officer Michael Trotsky more flexibility on VC fund investments.

Insurers and other industry insiders say the SEC’s proposed indemnification rule, combined with other potential regulations outlined in the agency’s February announcement, will impact this corner of the industry.